Skip to content

Lung adenocarcinoma — immunotherapy

TL;DR — For metastatic adenocarcinoma without an actionable driver, pembrolizumab plus platinum-pemetrexed is a first-line anchor: KEYNOTE-189 reduced mortality versus chemotherapy (HR 0.49 at the first report) across PD-L1 strata (Gandhi 2018, PMID 29658856). PD-L1-high tumors can receive checkpoint monotherapy, but PD-L1 is spatially variable and does not override the need for comprehensive genotyping (Reck 2016, PMID 27718847). EGFR-, ALK-, ROS1-, and RET-driven cancers usually derive less benefit from single-agent checkpoint blockade than smoking-associated driver-negative disease; giving immunotherapy before the molecular result can also complicate later TKI safety (Lisberg 2018, PMID 29874546; Lindeman 2018, PMID 29398453). STK11 and KEAP1 define adverse immune states; randomized POSEIDON subgroup and translational data support CTLA-4-containing chemo-immunotherapy as a resistance-mitigating hypothesis, but these markers are not yet validated stand-alone selectors (Skoulidis 2018, PMID 29773717; Ricciuti 2022, PMID 34740862; Skoulidis 2024, PMID 39385035). Durable survival tails are real, but most patients eventually develop primary or acquired resistance, and no universal post-chemo-immunotherapy sequence exists.

Treatment-selection boundary

Before choosing immunotherapy, establish histology, stage, performance status, actionable genotype, PD-L1 assay and tumor proportion score (TPS), autoimmune/transplant context, symptom tempo, and CNS burden.

Molecular state Default evidence direction Why PD-L1 alone is insufficient
EGFR sensitizing mutation EGFR-targeted therapy first PD-L1 positivity did not rescue pembrolizumab activity in a small TKI-naive trial (PMID 29874546)
ALK/ROS1/RET/NTRK fusion Matched TKI first Fusion-driven, never-smoker tumors often have lower effective neoantigen exposure; targeted trials show high response
KRAS G12C First-line choice still integrates PD-L1 and clinical state; G12C inhibitors historically later line STK11/KEAP1/TP53 context modifies outcomes (PMIDs: 29773717, 34740862)
No actionable driver PD-L1-guided monotherapy or chemo-IO KEYNOTE-024 and KEYNOTE-189 provide complementary paths (PMIDs: 27718847, 29658856)

Pivotal first-line evidence

Trial Population Regimen Efficacy Main boundary
KEYNOTE-024 PD-L1 TPS ≥50%, EGFR/ALK-negative NSCLC Pembrolizumab vs platinum chemo PFS 10.3 vs 6.0 mo; HR 0.50; ORR 44.8% vs 27.8% Selected high-PD-L1 population (PMID 27718847)
KEYNOTE-189 Metastatic nonsquamous NSCLC without EGFR/ALK Pembrolizumab + platinum-pemetrexed vs chemotherapy Initial OS HR 0.49; PFS HR 0.52 Combination benefit across PD-L1 strata (PMID 29658856)
IMpower150 Metastatic nonsquamous NSCLC Atezolizumab + bevacizumab + carboplatin/paclitaxel vs bevacizumab-chemo OS and PFS benefit for ABCP Four-drug toxicity and regimen complexity (PMID 29863955)
CheckMate 227 Advanced NSCLC Nivolumab + ipilimumab vs chemotherapy Durable OS benefit across PD-L1 strata CTLA-4 toxicity; TMB did not become universal selector (PMID 34648948)
CheckMate 9LA Advanced NSCLC Nivolumab + ipilimumab + two chemo cycles Durable long-term benefit Mixed histology; early chemo mitigates rapid progression risk (PMID 39270380)
EMPOWER-Lung 1 PD-L1 ≥50% NSCLC Cemiplimab vs chemotherapy OS/PFS improvement Driver-negative, PD-L1-selected population (PMID 40118215)

KEYNOTE-189 is directly relevant because it enrolled nonsquamous disease and used pemetrexed, the histology-preferred chemotherapy backbone. The trial does not show that every adenocarcinoma needs combination therapy; it shows that adding pembrolizumab improves outcomes in the eligible population (Gandhi 2018, PMID 29658856).

PD-L1: useful, not sovereign

PD-L1 TPS estimates the percentage of viable tumor cells with membranous staining. Assays, cutoffs, specimen age, treatment exposure, biopsy site, tumor heterogeneity, and reader variability change classification.

TPS stratum Common evidence-supported frame Important modifier
≥50% Checkpoint monotherapy or chemo-IO Rapid symptoms, large burden, brain/liver disease, and need for response may favor combination
1%–49% Chemo-IO usually provides stronger randomized support than monotherapy alone Frailty and contraindications can change net value
<1% Chemo-IO or other combination strategy Negative PD-L1 does not mean immune therapy cannot help

A pooled five-year analysis in PD-L1-negative metastatic NSCLC found OS HR 0.64 and PFS HR 0.66 for pembrolizumab-chemotherapy versus chemotherapy, but it combined nonsquamous and squamous trials and is not an adenocarcinoma-only estimate (Gadgeel 2024, PMID 38642841).

Driver-positive disease

The phase II pembrolizumab study in EGFR-mutant, PD-L1-positive, TKI-naive NSCLC stopped for futility after no objective responses among eligible EGFR-mutant patients, despite enrichment for PD-L1 expression (Lisberg 2018, PMID 29874546). Small sample size limits precision but the study directly refutes PD-L1 as a reason to bypass EGFR therapy.

IMpower150 subgroup analyses suggested that atezolizumab-bevacizumab-chemotherapy may have activity after TKI failure in EGFR-mutant disease, but exploratory subgroup evidence does not replace driver-directed therapy or prove the optimal post-TKI immune regimen (Reck 2019, PMID 30922878; Nogami 2022, PMID 34626838).

RET-fusion disease provides a randomized contrast: first-line selpercatinib prolonged PFS versus platinum-pemetrexed with or without pembrolizumab (Zhou 2023, PMID 37870973). The lesson is operational—complete genotyping before an irreversible first treatment choice.

Tumor-genomic context

STK11 and KEAP1

STK11/LKB1-mutant KRAS adenocarcinoma showed low response to PD-1 blockade and immune exclusion in retrospective and translational analyses (Skoulidis 2018, PMID 29773717). KEAP1-mutant tumors can retain high measured TMB yet show poor immune response, illustrating why mutation count is not equivalent to productive antitumor immunity (Marinelli 2020, PMID 32866624).

These biomarkers are intertwined with smoking, KRAS, stage, metabolic state, treatment, and prognosis. POSEIDON subgroup and laboratory analyses found benefit from durvalumab–tremelimumab–chemotherapy, but not durvalumab–chemotherapy, in STK11- and/or KEAP1-altered tumors; because this was a biomarker subgroup rather than a dedicated biomarker-randomized trial, it is hypothesis-strengthening rather than a universal selection rule (Skoulidis 2024, PMID 39385035).

TP53 and immune phenotype

TP53 co-mutation often correlates with higher inflammatory signaling in KRAS disease, while TP53 dysfunction also drives chromosomal instability and mixed targeted-therapy response. It is a contextual biomarker, not a licensed treatment selector (Hobor 2024, PMID 38871738; TCGA 2014, PMID 25079552).

Primary and acquired resistance

Resistance domain Examples Current clinical status
Antigen scarcity Never-smoker/low-tobacco mutational history Associated with lower average response; not deterministic
Antigen-presentation failure HLA loss, B2M defects Mostly retrospective/mechanistic
Immune exclusion STK11, KEAP1, myeloid-rich stroma CTLA-4-containing chemo-IO has randomized subgroup support; prospective biomarker validation remains incomplete (PMID 39385035)
Alternative checkpoints LAG-3, TIGIT, TIM-3 Multiple trials; no universal NSCLC rescue standard
Adaptive tumor evolution Loss of neoantigens, interferon-pathway defects Requires paired pre/post-treatment sampling
Pharmacologic limitation Steroids, poor exposure, treatment interruption Confounded by illness severity and indication

“Hyperprogression” remains a debated radiographic-clinical construct because definitions vary and aggressive natural history can mimic treatment acceleration. It should not be diagnosed from a single early scan without baseline growth context.

Duration and stopping

Pembrolizumab trials commonly capped treatment at 35 cycles. Long-term survivors who complete planned therapy are a selected group conditioned on remaining alive and controlled; their outcomes cannot be applied prospectively to every new patient.

Questions after two years include whether to stop, continue, re-treat at relapse, or use ctDNA to refine the decision. Randomized evidence comparing indefinite with fixed-duration checkpoint therapy in this exact setting remains limited.

Checkpoint toxicity can affect any organ and may occur during or after treatment. ASCO guidance generally continues with monitoring for many grade-1 events, holds most grade-2 events, gives systemic corticosteroids for grade-3 toxicity, and permanently stops for most grade-4 toxicity, with organ-specific exceptions (Schneider 2021, PMID 34724392).

Syndrome Signals Immediate concern
Pneumonitis New cough, dyspnea, hypoxemia, ground-glass or organizing pattern Infection, progression, embolism, and radiation injury are competing diagnoses (PMID 27535979)
Myocarditis Chest pain, dyspnea, troponin rise, conduction disease Can deteriorate rapidly; myositis/myasthenia overlap (PMIDs: 31960755, 30925516)
Colitis Diarrhea, pain, blood, dehydration Infection and perforation
Hepatitis Rising transaminases/bilirubin Metastases, obstruction, viral/drug injury
Endocrinopathy Fatigue, hypotension, headache, sodium/glucose change Adrenal crisis, hypophysitis, thyroid dysfunction
Neurologic Weakness, ptosis, neuropathy, confusion Respiratory failure and overlap syndromes

See red flags and safety concerns for action windows and differential diagnosis.

Special populations

  • Autoimmune disease: risk depends on organ, activity, immunosuppression, and consequences of flare; trial exclusions limit certainty.
  • Solid-organ transplant: rejection can be catastrophic; specialist risk assessment is essential.
  • ECOG 2–3: pivotal trials largely enrolled performance status 0–1; illness due to cancer is different from fixed comorbidity.
  • Brain metastases: symptomatic lesions usually need local-therapy assessment regardless of systemic activity (Vogelbaum 2022, PMID 34932393).
  • Older adults: chronological age alone does not encode frailty, cognition, renal function, or goals.

Open questions

  • Which prospectively validated composite outperforms PD-L1 alone for monotherapy versus chemo-IO selection?
  • Are STK11 and KEAP1 predictive of regimen interaction or primarily adverse prognostic states (PMIDs: 29773717, 34740862)?
  • What is the best post-chemo-IO treatment sequence in driver-negative adenocarcinoma?
  • Can ctDNA kinetics justify early escalation, de-escalation, or duration changes?
  • Which patients can safely stop checkpoint therapy at two years, and who benefits from re-treatment?
  • How can patients with autoimmune disease, transplant, frailty, and ECOG 2–3 be studied without unsafe generalization?

References

  1. Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018. PMID 29658856
  2. Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016. PMID 27718847
  3. Socinski MA, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018. PMID 29863955
  4. Reck M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019. PMID 30922878
  5. Nogami N, et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol. 2022. PMID 34626838
  6. Paz-Ares LG, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2022. PMID 34648948
  7. Reck M, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024. PMID 39270380
  8. Kilickap S, et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025. PMID 40118215
  9. Gadgeel SM, et al. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024. PMID 38642841
  10. Lisberg A, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018. PMID 29874546
  11. Zhou C, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023. PMID 37870973
  12. Skoulidis F, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018. PMID 29773717
  13. Ricciuti B, et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022. PMID 34740862
  14. Marinelli D, et al. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 2020. PMID 32866624
  15. Scalera S, et al. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. J Thorac Oncol. 2021. PMID 34450259
  16. Scalera S, et al. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma. Ann Oncol. 2023. PMID 36526124
  17. Hobor S, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nat Commun. 2024. PMID 38871738
  18. Cancer Genome Atlas Research Network, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014. PMID 25079552
  19. Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018. PMID 29398453
  20. Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021. PMID 34724392
  21. Nishino M, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016. PMID 27535979
  22. Palaskas N, et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020. PMID 31960755
  23. Raikhelkar J, et al. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 2019. PMID 30925516
  24. Vogelbaum MA, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022. PMID 34932393
  25. Rolfo C, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021. PMID 34246791
  26. Skoulidis F, et al. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024. PMID 39385035